Diagnosis and prediction of disease progression in Alcohol-related Liver Disease (ALD), especially in cirrhosis, has proven difficult. Our diagnostic and prognostic biomarkers have the potential to greatly benefit patients by helping in the early diagnosis of the disease and initiating the most appropriate treatment at the right time.

There is an urgent need for novel biomarkers that can adequately determine the risk of disease progression as well as early response to treatment. Fibrosis is a key histological feature of immune-mediated liver disease; however, the severity of liver fibrosis is primarily determined by liver biopsy. Our biomarkers are being used in clinical trials to detect rapid disease progression and monitor treatment efficacy.

Metabolic diseases like MAFLD/MASH, kidney disease, and heart failure often involve increased fibroblast activity and fibrosis. Our biomarkers provide key insights into disease activity and risk, supporting earlier diagnosis, better patient stratification, and treatment monitoring.

Viral liver diseases, such as hepatitis B and C, are major global health challenges that often lead to chronic inflammation and liver fibrosis. While traditional diagnostics provide some insight, there remains a significant need for non-invasive tools that can more accurately predict disease progression, monitor treatment response, and stratify patients for clinical trials. At Nordic Bioscience, our ProteinFingerPrint™ biomarkers offer a novel approach to quantifying liver tissue remodeling in viral hepatitis—enabling earlier intervention, supporting drug development, and guiding personalized treatment strategies.